Welcome to our dedicated page for NUGEN MEDICAL DEVICES news (Ticker: NGMDF), a resource for investors and traders seeking the latest updates and insights on NUGEN MEDICAL DEVICES stock.
NuGen Medical Devices Inc. develops needle-free devices for subcutaneous drug delivery, centered on the InsuJet™ system for insulin administration and related consumables. Company news commonly covers commercialization of InsuJet and EziAutoJector® through distributors and pharmacy channels, product availability in markets such as France and the United Kingdom, and medical-device regulatory updates tied to national approvals and licensing.
NuGen updates also include research and development for prefilled and cartridge-based needle-free injection formats, patent activity for Ready-to-Fill COP/COC nozzles and the Prefilled Nozzle platform, annual financial results, and governance changes involving financial reporting functions.
NuGen Medical Devices has announced the successful completion of sales and clinical training for its needle-free device, InsuJet, with Sol-Millennium Medical in Brazil. This marks a key step for introducing InsuJet into the Brazilian market, a significant growth target given its population of over 200 million. The training, completed on June 26, 2024, follows recent purchase orders for Canada and Europe, underscoring NuGen's expanding global footprint. CEO Ian Heynen anticipates imminent purchase orders, highlighting the importance of this development in NuGen's South American strategy.
NuGen Medical Devices announced a repeat order from Rosheta for 1,100 InsuJet™ units and consumables, valued at $147,000, to meet increasing demand in Yemen. This order represents a 37.5% increase from the initial order of 800 units placed in January 2024. The gross margin contribution on this sale is $102,900. Rosheta's marketing plan aims to expand nationwide distribution of InsuJet™, a needle-free injector. CEO Ian Heynen praised Rosheta's efforts to penetrate the Yemeni market through clinical marketing strategies at both pharmacy and physician levels.
NuGen Medical Devices announced an initial purchase order from Sol-Millennium for 3,832 InsuJet injectors and consumables, destined for pharmacies in Canada and Switzerland. This order, worth $801,000, will generate a gross margin of $448,000 for NuGen, more than double its total revenue for fiscal year 2023. Deliveries are scheduled for August through September 2024, with 3,282 units allocated to Canadian pharmacies and 550 units to Swiss pharmacies. This significant order reflects growing market demand and NuGen's accelerating growth.
NuGen Medical Devices (TSXV: NGMD) released its Q1 2024 financial results, meeting management's expectations. The company focused on preparing its new distribution channels in major markets including Canada, Europe, Brazil, and Mexico. Post-Q1, NuGen renegotiated its long-term debt, improving its balance sheet. The company aims for growth in InsuJetTM sales, driven by patient awareness, distribution expansion, and clinical community education. New distribution partners in Thailand, Argentina, Colombia, Peru, and Costa Rica were appointed. NuGen's CEO Ian Heynen, who joined in November 2023, emphasized the company's potential and strategic efforts for 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.